JAMA Clinical Evidence Synopsis
January 8, 2014

Pharmacological Treatments for Smoking Cessation

Author Affiliations
  • 1Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
  • 2Cochrane Tobacco Addiction Group, University of Oxford, Oxford, United Kingdom

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;311(2):193-194. doi:10.1001/jama.2013.283787

Clinical Question  Among the 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in helping people who smoke achieve and maintain abstinence from smoking for at least 6 months, and what serious adverse events are associated with each?

Bottom Line  Higher rates of smoking cessation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%). Varenicline (27.6%) and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessation. None of the therapies was associated with an increased rate of serious adverse events.